ABBV peer analysis
AbbVie (ABBV) against its competitors: price, today's move, 1-year return and market value side by side.
ABBV and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| AMGN Amgen | $466.01 | 1.15% | 59.59% | $249.09B |
| AZN AstraZeneca | $186.65 | 7.02% | 13.34% | $270.48B |
| BMY Bristol-Myers Squibb | $62.48 | 1.78% | 36.96% | $125.49B |
| GSK GSK | $49.24 | -0.55% | 4.90% | $97.53B |
| JNJ Johnson & Johnson | $272.61 | -0.22% | 44.20% | $662.49B |
| LLY Eli Lilly | $1,412.98 | -0.32% | 67.32% | $1.22T |
| MRK Merck | $149.00 | -0.35% | 72.69% | $361.02B |
| NVS Novartis | $160.79 | -0.19% | 31.14% | $304.26B |
| PFE Pfizer | $30.45 | -0.23% | 25.36% | $170.71B |
| ABBV AbbVie | $294.89 | 1.41% | 29.22% | $513.86B |
- ABBV's peers: AMGN (Amgen), AZN (AstraZeneca), BMY (Bristol-Myers Squibb), GSK (GSK), JNJ (Johnson & Johnson), LLY (Eli Lilly), MRK (Merck), NVS (Novartis).
Updated 2026-11-02 17:55 UTC